Everspin Technologies Inc.: Form 10-Q for the period ended Sep 30, 2025
Filed with the SEC on Nov 5, 2025 and accepted by EDGAR at Nov 5, 2025, 22:24 ET.
Management's discussion and analysis
As filed, 26,940 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and related notes included in Part I, Item 1 of this report and with our audited financial statements and related notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2024.
Forward-Looking Statements
This discussion contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). Forward-looking statements are identified by words such as “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “could,” “potentially” or the negative of these terms or similar expressions. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other “forward-looking” information. These statements relate to, among other things, our industry, business, future plans, strategies, objectives, expectations, intentions and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this report in Part II, Item 1A — “Risk Factors,” and elsewhere in this report, as well as in our other filings with the Securities and Exchange Commission (SEC). Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into or review of, all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely on these statements. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.
Overview
Everspin is a pioneer in the successful commercialization of Magnetoresistive Random Access Memory (MRAM) technology. Our portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), is delivering superior performance, persistence and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. With over 15 years of MRAM technology and manufacturing leadership, our memory solutions deliver significant value to our customers in key markets such as industrial, medical, automotive/transportation, aerospace and data center. We are the leading supplier of discrete MRAM components and a successful licensor of our broad portfolio of related technology intellectual property.
We sell our products directly and through our established distribution channels to industry-leading OEMs and ODMs.
We manufacture our MRAM products using both captive and third-party manufacturing capabilities. We purchase industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes our magnetic-bit technology at our 200mm fabrication facility in Chandler, Arizona. We also manufacture full-flow 300mm CMOS wafers with our STT-MRAM magnetic-bit technology integrated in BEOL as part of our strategic relationship with GLOBALFOUNDRIES.
Key Metrics
We monitor a variety of key financial metrics to help us evaluate trends, establish budgets, measure the effectiveness of our business strategies, and assess operational efficiencies. These financial metrics include revenue, gross margin, operating expenses and operating income determined in accordance with GAAP. Additionally, we monitor and project cash flow to determine our sources and uses for working capital to fund our operations. We also monitor Adjusted net income, a non-GAAP financial measure, and design wins. We define Adjusted net income as net income adjusted for stock-based compensation expense.
Adjusted net income. Our management and board of directors use Adjusted net income to assess and evaluate our overall performance and financial trends, inform the annual budgeting process, and guide both short-term and long-term operational and strategic planning. As such, we believe Adjusted net income provides meaningful insight for investors into our financial performance, consistent with how our management team and board view and analyze our results. Adjusted net income is a non-GAAP financial measure and should be considered alongside, but not as a replacement for or superior to, net income as reported in accordance with GAAP. The following table provides a reconciliation of net income, the most directly comparable GAAP measure, to Adjusted net income for the periods presented:
(in thousands)
| Adjusted Net Income (Loss) reconciliation: | Three Months Ended September 30, 2025 | 2024 | Nine Months Ended September 30, 2025 | 2024 |
|---|---|---|---|---|
| Net income (loss) | $54 | $2,271 | $(1,782) | $(433) |
| Stock-based compensation expense | 1,407 | 1,532 | 4,403 | 5,108 |
| Adjusted Net Income (Loss) | $1,461 | $3,803 | $2,621 | $4,675 |
Results of Operations
The following tables set forth our results of operations for the periods indicated:
(In thousands)
| Three Months Ended September 30, 2025 | 2024 | 2025 (As a percentage of revenue) | 2024 | |
|---|---|---|---|---|
| Product sales | $12,690 | $10,443 | 90% | 86% |
| Licensing, royalty, patent, and other revenue | 1,370 | 1,650 | 10 | 14 |
| Total revenue | 14,060 | 12,093 | 100 | 100 |
| Cost of product sales | 6,628 | 5,751 | 47 | 48 |
| Cost of licensing, royalty, patent, and other revenue | 226 | 390 | 2 | 3 |
| Total cost of sales | 6,854 | 6,141 | 49 | 51 |
| Gross profit | 7,206 | 5,952 | 51 | 49 |
| Operating expenses: | ||||
| Research and development | 3,583 | 3,384 | 25 | 28 |
| General and administrative | 3,690 | 3,363 | 26 | 28 |
| Sales and marketing | 1,478 | 1,320 | 11 | 11 |
| Total operating expenses | 8,751 | 8,067 | 62 | 67 |
| Loss from operations | (1,545) | (2,115) | (11) | (17) |
| Interest income | 432 | 463 | 3 | 3 |
| Other income, net | 1,164 | 3,933 | 8 | 33 |
| Net income before income taxes | 51 | 2,281 | — | 19 |
| Income tax benefit (expense) | 3 | (10) | — | — |
| Net income and comprehensive income | $54 | $2,271 | —% | 19% |
19
Comparison of the three months ended September 30, 2025 and 2024
Revenue
We generated 86% and 84% of our revenue from products sold to distributors for the three months ended September 30, 2025 and 2024, respectively.
In addition to selling our products to our distributors, we maintain a direct selling relationship, for strategic purposes, with several key customer accounts. We have organized our sales team and representatives into three primary regions: North America; EMEA; and APAC. We recognize revenue by geography based on the region in which our customer is located and to which our products are sold, and not to where the end products in which they are assembled are shipped. Our revenue by region and by type of revenue for the periods indicated were as follows (in thousands):
| Three Months Ended September 30, 2025 | 2024 | |
|---|---|---|
| APAC | $8,571 | $7,923 |
| North America | 2,497 | 1,874 |
| EMEA | 2,992 | 2,296 |
| Total revenue | $14,060 | $12,093 |
(Dollars in thousands)
| Three Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| Product sales | $12,690 | $10,443 | $2,247 | 21.5% |
| Licensing, royalty, patent, and other revenue | 1,370 | 1,650 | (280) | (17.0)% |
| Total revenue | $14,060 | $12,093 | $1,967 | 16.3% |
Total revenue increased by $2.0 million, or 16.3%, from $12.1 million during the three months ended September 30, 2024 to $14.1 million during the three months ended September 30, 2025. The increase was due to an increase in product sales of $2.2 million, and partially offset by a decrease of licensing, royalty, patent, and other revenue of $0.3 million.
Licensing, royalty, patent, and other revenue is a highly variable revenue item characterized by a small number of transactions annually with revenue based on size and terms of each transaction. Licensing, royalty, patent, and other revenue decreased by $0.3 million, or 17.0% from $1.7 million during the three months ended September 30, 2024, to $1.4 million during the three months ended September 30, 2025. The decrease was primarily due to the reduced pace of deliverables in our contractual agreements with customers for the development of RAD-Hard products, along with the conclusion of a contractual arrangement with a customer for the development of reliability models for strategic radiation hardened toggle MRAM, and partially offset by a new agreement for the development of an AI technology application.
Cost of Sales and Gross Margin
(Dollars in thousands)
| Three Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| Cost of product sales | $6,628 | $5,751 | $877 | 15.2% |
| Cost of licensing, royalty, patent, and other revenue | 226 | 390 | (164) | (42.1)% |
| Total cost of sales | $6,854 | $6,141 | $713 | 11.6% |
| Gross margin | 51.3% | 49.2% |
Cost of product sales increased by $0.9 million, or 15.2%, from $5.8 million during the three months ended September 30, 2024, to $6.6 million during the three months ended September 30, 2025. Cost of product sales relate primarily to costs of our toggle and STT products.
Cost of licensing, royalty, patent, and other revenue slightly decreased by $0.2 million, or 42.1% from $0.4 million during the three months ended September 30, 2024, to $0.2 million during the three months ended September 30, 2025. The decrease was primarily due to a decrease in licensing costs related to labor and materials associated with the progression of our RAD-Hard projects.
Gross margin increased from 49.2% during the three months ended September 30, 2024, to 51.3% during the three months ended September 30, 2025. Gross margin increased as a result of improved yields and improved fabrication facility ("Fab") utilization.
Operating Expenses
Our operating expenses consist of research and development, general and administrative and sales and marketing expenses. Personnel-related expenses, including salaries, benefits, bonuses and stock-based compensation, are among the most significant components of each of our operating expense categories.
(Dollars in thousands)
| Three Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| Research and development | $3,583 | $3,384 | $199 | 5.9% |
| Research and development as a % of revenue | 25% | 28% |
Research and Development Expenses. Research and development expenses increased by $0.2 million, or 5.9%, from $3.4 million during the three months ended September 30, 2024, to $3.6 million during the three months ended September 30, 2025. Research and development expenses relate primarily to the development and enhancement of our new Extended Serial Peripheral Interface (xSPI) family of STT-MRAM products, which offer high-performance, multiple I/O, SPI-compatibility and feature a high-speed, low pin count SPI compatible interface.
(Dollars in thousands)
| Three Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| General and administrative | $3,690 | $3,363 | $327 | 9.7% |
| General and administrative as a % of revenue | 26% | 28% |
General and Administrative Expenses. General and administrative expenses increased by $0.3 million, or 9.7%, from $3.4 million during the three months ended September 30, 2024, to $3.7 million during the three months ended September 30, 2025. The increase is primarily due to increases in professional service fees.
(Dollars in thousands)
| Three Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| Sales and marketing | $1,478 | $1,320 | $158 | 12.0% |
| Sales and marketing as a % of revenue | 11% | 11% |
Sales and Marketing Expenses. Sales and marketing expenses increased by $0.2 million, or 12.0%, from $1.3 million during the three months ended September 30, 2024, to $1.5 million during the three months ended September 30, 2025. Sales and marketing expenses relate primarily to compensation costs and contract labor.
(Dollars in thousands)
| Three Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| Interest income | $432 | $463 | $(31) | (6.7)% |
Interest income decreased by $31,000, or 6.7%, from $0.5 million interest income during the three months ended September 30, 2024, to $0.4 million interest income during the three months ended September 30, 2025. The decrease is primarily due to the decrease in interest rates.
Other Income, Net
(Dollars in thousands)
| Three Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| Other income, net | $1,164 | $3,933 | $(2,769) | (70.4)% |
Other income, net decreased by $2.8 million, or 70.4%, from $3.9 million other expense during the three months ended September 30, 2024, to $1.2 million other income during the three months ended September 30, 2025. Other income relates primarily to other income recognized from a strategic award we received to develop a long-term plan to provide manufacturing services for aerospace and defense segments.
(In thousands)
| Nine Months Ended September 30, 2025 | 2024 | 2025 (As a percentage of revenue) | 2024 | |
|---|---|---|---|---|
| Product sales | $34,807 | $31,190 | 86% | 84% |
| Licensing, royalty, patent, and other revenue | 5,592 | 5,969 | 14 | 16 |
| Total revenue | 40,399 | 37,159 | 100 | 100 |
| Cost of product sales | 18,823 | 16,989 | 47 | 46 |
| Cost of licensing, royalty, patent, and other revenue | 849 | 842 | 2 | 2 |
| Total cost of sales | 19,672 | 17,831 | 49 | 48 |
| Gross profit | 20,727 | 19,328 | 51 | 52 |
| Operating expenses: | ||||
| Research and development | 10,519 | 10,259 | 26 | 28 |
| General and administrative | 11,170 | 10,653 | 28 | 29 |
| Sales and marketing | 4,476 | 3,950 | 11 | 11 |
| Total operating expenses | 26,165 | 24,862 | 65 | 67 |
| Loss from operations | (5,438) | (5,534) | (13) | (15) |
| Interest income | 1,263 | 1,325 | 3 | 4 |
| Other income, net | 2,394 | 3,862 | 6 | 10 |
| Net loss before income taxes | (1,781) | (347) | (4) | (1) |
| Income tax expense | (1) | (86) | — | — |
| Net loss and comprehensive loss | $(1,782) | $(433) | (4)% | (1)% |
Comparison of the nine months ended September 30, 2025 and 2024
Revenue
We generated 71% and 80% of our revenue from products sold to distributors for the nine months ended September 30, 2025 and 2024, respectively.
Our revenue by region and by type of revenue for the periods indicated were as follows (in thousands).
| Nine Months Ended September 30, 2025 | 2024 | |
|---|---|---|
| APAC | $24,412 | $21,163 |
| North America | 7,906 | 7,857 |
| EMEA | 8,081 | 8,139 |
| Total revenue | $40,399 | $37,159 |
(Dollars in thousands)
| Nine Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| Product sales | $34,807 | $31,190 | $3,617 | 11.6% |
| Licensing, royalty, patent, and other revenue | 5,592 | 5,969 | (377) | (6.3)% |
| Total revenue | $40,399 | $37,159 | $3,240 | 8.7% |
23
Total revenue increased by $3.2 million, or 8.7%, from $37.2 million during the nine months ended September 30, 2024 to $40.4 million during the nine months ended September 30, 2025. The increase was due to increase in product sales revenue of $3.6 million.
Licensing, royalty, patent, and other revenue decreased by $0.4 million, or 6.3% from $6.0 million during the nine months ended September 30, 2024, to $5.6 million during the nine months ended September 30, 2025. The decrease was primarily due to the conclusion of a contractual arrangement with a customer for the development of reliability models for strategic radiation hardened toggle MRAM, and by the reduced pace of deliverables in our contractual agreements with customers for the development of RAD-Hard products a new agreement for the development of an AI technology application.
Cost of Sales and Gross Margin
(Dollars in thousands)
| Nine Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| Cost of product sales | $18,823 | $16,989 | $1,834 | 10.8% |
| Cost of licensing, royalty, patent, and other revenue | 849 | 842 | 7 | 0.8% |
| Total cost of sales | $19,672 | $17,831 | $1,841 | 10.3% |
| Gross margin | 51.3% | 52.0% |
Cost of product sales increased by $1.8 million, or 10.8%, from $17.0 million during the nine months ended September 30, 2024, to $18.8 million during the nine months ended September 30, 2025. Cost of product sales relate primarily to costs of our toggle and STT products.
Cost of licensing, royalty, patent, and other revenue remained consistent at $0.8 million during the nine months ended September 30, 2024 and 2025, respectively.
Gross margin decreased from 52.0% during the nine months ended September 30, 2024, to 51.3% during the nine months ended September 30, 2025. Gross margin decreased as a result of a decrease in other revenue.
Operating Expenses
Our operating expenses consist of research and development, general and administrative and sales and marketing expenses. Personnel-related expenses, including salaries, benefits, bonuses and stock-based compensation, are among the most significant components of each of our operating expense categories.
(Dollars in thousands)
| Nine Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| Research and development | $10,519 | $10,259 | $260 | 2.5% |
| Research and development as a % of revenue | 26% | 28% |
Research and Development Expenses
Research and development expenses increased by $0.3 million, or 2.5%, from $10.3 million during the nine months ended September 30, 2024, to $10.5 million during the nine months ended September 30, 2025. Research and development expenses relate primarily to the development and enhancement of our new Extended Serial Peripheral Interface (xSPI) family of STT-MRAM products, which offer high-performance, multiple I/O, SPI-compatibility and feature a high-speed, low pin count SPI compatible interface.
(Dollars in thousands)
| Nine Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| General and administrative | $11,170 | $10,653 | $517 | 4.9% |
| General and administrative as a % of revenue | 28% | 29% |
General and Administrative Expenses. General and administrative expenses increased by $0.5 million, or 4.9%, from $10.7 million during the nine months ended September 30, 2024, to $11.2 million during the nine months ended September 30, 2025. The increase is primarily due to one-time professional service fees.
(Dollars in thousands)
| Nine Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| Sales and marketing | $4,476 | $3,950 | $526 | 13.3% |
| Sales and marketing as a % of revenue | 11% | 11% |
Sales and Marketing Expenses. Sales and marketing expenses increased by $0.5 million, or 13.3%, from $4.0 million during the nine months ended September 30, 2024, to $4.5 million during the nine months ended September 30, 2025. Sales and marketing expenses relate primarily to compensation costs and contract labor.
(Dollars in thousands)
| Nine Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| Interest income | $1,263 | $1,325 | $(62) | (4.7)% |
Interest income remained consistent at $1.3 million during the nine months ended September 30, 2024 and 2025, respectively.
Other Income, Net
(Dollars in thousands)
| Nine Months Ended September 30, 2025 | 2024 | Change Amount% | ||
|---|---|---|---|---|
| Other income, net | $2,394 | $3,862 | $(1,468) | (38.0)% |
Other income, net decreased by $1.5 million, or 38.0%, from $3.9 million other expense during the nine months ended September 30, 2024, to $2.4 million other income during the nine months ended September 30, 2025. Other income relates primarily to income recognized from a strategic award we received to develop a long-term plan to provide manufacturing services for aerospace and defense industries.
On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. We are currently assessing its impact on our consolidated financial statements.
Liquidity and Capital Resources
As of September 30, 2025, we had $45.3 million of cash and cash equivalents, compared to $42.1 million as of December 31, 2024. We believe our cash and cash equivalents are sufficient to meet our anticipated capital requirements in the next 12 months. Our long-term capital requirements will depend on many factors, including, among other things, our growth rate, the timing and extent of our spending to support research and development activities, the timing and cost of establishing additional sales and marketing capabilities, and the introduction of new products.
Cash Flows
The following table summarizes our cash flows for the periods indicated (in thousands):
(In thousands)
| Nine Months Ended September 30, 2025 | 2024 | |
|---|---|---|
| Cash provided by operating activities | $7,336 | $3,266 |
| Cash used in investing activities | (4,733) | (1,302) |
| Cash provided by financing activities | 557 | 678 |
Cash Flows From Operating Activities
During the nine months ended September 30, 2025, cash provided by operating activities was $7.3 million, which consisted of net loss of $1.8 million, non-cash charges of $6.9 million and changes of net operating assets and liabilities of $2.2 million. The non-cash charges consisted of stock-based compensation of $4.4 million and depreciation and amortization of $2.6 million. The change in our net operating assets and liabilities was primarily due to a decrease in accounts receivable of $3.0 million, an increase in deferred revenue of $0.9 million, an increase in accrued liabilities of $0.5 million, an increase in contract obligation of $0.5 million, a decrease in prepaid and other current assets of $0.4 million, an increase in long-term income tax liability of $0.1 million, offset by an increase in inventory of $2.7 million and a decrease in accounts payable of $0.6 million.
During the nine months ended September 30, 2024, cash provided by operating activities was $3.3 million, which consisted of net loss of $0.4 million, non-cash charges of $6.3 million and changes of net operating assets and liabilities of $2.6 million. The non-cash charges primarily consisted of stock-based compensation of $5.1 million, depreciation and amortization of $1.2 million. The change in our net operating assets and liabilities was primarily due to an increase in accounts payable of $0.2 million, an increase in contract obligations of $3.0 million, an increase in prepaid and other current assets of $3.6 million, a decrease in accounts receivable of $0.1 million due to timing of cash receipts for outstanding balances, and a decrease in accrued liabilities of $2.2 million.
Cash Flows From Investing Activities
Cash used in investing activities during the nine months ended September 30, 2025 was $4.7 million due to $3.2 million of purchases of manufacturing equipment and $1.5 million in purchases of intangible assets.
Cash used in investing activities during the nine months ended September 30, 2024 was $1.3 million, reflecting purchases of manufacturing equipment.
Cash Flows From Financing Activities
Cash provided by financing activities during the nine months ended September 30, 2025 was $0.6 million, primarily due to proceeds from the exercise of employee stock options and purchase of shares under our employee stock purchase plan offset by a nominal amount in payments on finance leases.
Cash provided by financing activities during the nine months ended September 30, 2024 was $0.7 million, consisting of proceeds from the exercise of employee stock options and purchase of shares under our employee stock purchase plan.
Critical Accounting Policies and Significant Judgments and Estimates
Our condensed financial statements have been prepared in accordance with GAAP. The preparation of these condensed financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated, and expenses incurred during the reporting periods. We base our estimates on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
There have been no changes to our critical accounting policies and estimates described in the Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 27, 2025, that have had a material impact on our condensed financial statements and related notes.
Controls and procedures
As filed, 1,906 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of disclosure controls and procedures.
Our management, including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of September 30, 2025, the end of the period covered by this Quarterly Report on Form 10-Q.
Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2025.
There have been no changes in our internal control over financial reporting that occurred during the three and nine months ended September 30, 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent limitation on the effectiveness of internal control.
The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.
Risk factors
As filed, 625 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended December 31, 2024 and in “Part II, Item 1A. Risk Factors” of our quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-07-01 to 2025-09-30 | $14.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2025-01-01 to 2025-09-30 | $40.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-07-01 to 2025-09-30 | $6.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2025-01-01 to 2025-09-30 | $19.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-07-01 to 2025-09-30 | $7.2m | us-gaap:GrossProfit |
| Gross profit | 9 months2025-01-01 to 2025-09-30 | $20.7m | us-gaap:GrossProfit |
| Research and development | 3 months2025-07-01 to 2025-09-30 | $3.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2025-01-01 to 2025-09-30 | $10.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-07-01 to 2025-09-30 | −$1.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-01-01 to 2025-09-30 | −$5.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-07-01 to 2025-09-30 | −$3.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2025-01-01 to 2025-09-30 | $1.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-07-01 to 2025-09-30 | $54.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-01-01 to 2025-09-30 | −$1.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-07-01 to 2025-09-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-01-01 to 2025-09-30 | −$0.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-07-01 to 2025-09-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-01-01 to 2025-09-30 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-07-01 to 2025-09-30 | 23,147,119 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-01-01 to 2025-09-30 | 22,456,079 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-01-01 to 2025-09-30 | $7.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2025-01-01 to 2025-09-30 | $3.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-09-30 | $45.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-09-30 | $66.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-09-30 | $80.3m | us-gaap:Assets |
| Current liabilities | At period end2025-09-30 | $11.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-09-30 | $14.5m | us-gaap:Liabilities |
| Long-term debt | At period end2025-09-30 | $465.0k | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-09-30 | $1.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2025-09-30 | $65.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-25-049703. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.